Walter Farrell, MD
Internal Medicine · Lawrence, KSNPI 1750375663
Payments from drug & device makers
Across 98 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$164
- Amgen$152
- Lilly USA, LLC$151
- Novartis$118
- GSK$103
- Sunovion Pharmaceuticals Inc.$98
- plus $625 from 22 others
What the payments were for
- Food & beverage$1,412100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $164 |
| Amgen | 9 | $152 |
| Lilly USA, LLC | 10 | $151 |
| Novartis | 8 | $118 |
| GSK | 7 | $103 |
| Sunovion Pharmaceuticals Inc. | 14 | $98 |
| Boehringer Ingelheim | 5 | $82 |
| AstraZeneca | 3 | $44 |
| Astellas Pharma US Inc | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Grifols USA, LLC | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $33 |
| Exact Sciences | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 2 | $25 |
| Pfizer | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Exeltis, USA Inc. | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
How this compares
$1,412 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $111,294 |
| OzempicSemaglutide | 48 | $53,085 |
| JanuviaSitagliptin Phosphate | 48 | $45,006 |
| TrulicityDulaglutide | 23 | $28,005 |
| XareltoRivaroxaban | 32 | $23,364 |
| LinzessLinaclotide | 35 | $22,647 |
| JardianceEmpagliflozin | 16 | $19,995 |
| MyrbetriqMirabegron | 28 | $18,684 |
| MounjaroTirzepatide | 12 | $16,626 |
| Xtampza ErOxycodone Myristate | 12 | $13,529 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $11,141 |
| RybelsusSemaglutide | 11 | $10,446 |
| Repatha SyringeEvolocumab | 16 | $8,540 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $7,661 |
| OxycontinOxycodone Hcl | 11 | $6,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $23 | $115,520145 claims |
| Novo NordiskOzempic, Rybelsus | $164 | $63,53159 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $151 | $44,63135 claims |
| Johnson & JohnsonXarelto | $26 | $23,36432 claims |
| Boehringer IngelheimJardiance | $82 | $19,99516 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $18,68428 claims |
| GSKIncruse Ellipta | $103 | $7,66116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Lawrence
- Donna GriebelLawrence$786K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.